SHATTUCK LABS INC. - COMMON STOCK

1,2300

08-января-25 16:45:00

15 мин. задержка

Акции

-0,0400

-3,15%

Сегодняшний диапазон

1,2250 - 1,2800

ISIN

N/A

Источник

NASDAQ

Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference

04 янв 2024 16:05:00 Источник Nasdaq GlobeNewswire
Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

21 дек 2023 08:00:00 Источник Nasdaq GlobeNewswire
Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients

13 дек 2023 06:00:00 Источник Nasdaq GlobeNewswire
Shattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation Data from the American Society of Hematology (ASH) 2023 Annual Meeting on December 13, 2023

05 дек 2023 16:15:00 Источник Nasdaq GlobeNewswire
Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference

14 ноя 2023 09:00:00 Источник Nasdaq GlobeNewswire
Shattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business Highlights

09 ноя 2023 06:00:00 Источник Nasdaq GlobeNewswire
Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023

06 ноя 2023 09:28:40 Источник Nasdaq GlobeNewswire
Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023 Annual Meeting

02 ноя 2023 09:01:00 Источник Nasdaq GlobeNewswire
Shattuck Labs Reports Second Quarter 2023 Financial Results and Recent Business Highlights

10 авг 2023 16:00:00 Источник Nasdaq GlobeNewswire
Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

25 май 2023 17:15:39 Источник Nasdaq GlobeNewswire
Shattuck Labs Reports First Quarter 2023 Financial Results and Recent Business Highlights

09 май 2023 16:00:00 Источник Nasdaq GlobeNewswire
Shattuck Labs Announces Participation in Upcoming 22nd Annual Needham Virtual Healthcare Conference

03 апр 2023 07:00:00 Источник Nasdaq GlobeNewswire
Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting

16 мар 2023 08:31:26 Источник Nasdaq GlobeNewswire
Shattuck Labs Announces Participation in Upcoming March Conferences

01 мар 2023 07:00:00 Источник Nasdaq GlobeNewswire
Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates

23 фев 2023 16:30:00 Источник Nasdaq GlobeNewswire
Shattuck Labs to Report Fourth-Quarter and Full-Year 2022 Financial Results on February 23, 2023

16 фев 2023 07:00:00 Источник Nasdaq GlobeNewswire
Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference

09 фев 2023 06:01:00 Источник Nasdaq GlobeNewswire
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2023

09 янв 2023 07:00:01 Источник Nasdaq GlobeNewswire
Shattuck Labs Reports Third Quarter 2022 Financial Results and Recent Business Highlights

08 ноя 2022 16:30:00 Источник Nasdaq GlobeNewswire
Shattuck Labs Presents Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

07 ноя 2022 08:01:11 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.